Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme
May 07 2021 - 3:24PM
Novo Nordisk A/S purchases B shares worth DKK 2,586 million from
Novo Holdings A/S under the 2021 share repurchase programme
Bagsværd, Denmark, 7 May
2021 — Novo Nordisk A/S has today
entered into an agreement to purchase 5,610,000 B shares of DKK
0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This
transaction is part of Novo Nordisk A/S’ 2021 share repurchase
programme of up to a total of DKK 18 billion to be executed during
a 12-month period beginning 3 February 2021. The transaction price
is DKK 461.04 per share and has been calculated as the three-day
volume weighted average market price from 5 May 2021 to 7 May 2021
in the open window following the announcement of Novo Nordisk A/S’
quarterly financial results.
Prior to the sale of B shares, Novo Holdings A/S’ ownership of
Novo Nordisk A/S was 28.5% of the share capital and 76.9% of the
votes. Following the transaction, Novo Holdings A/S owns
537,436,000 A shares of DKK 0.20 and 116,129,000 B shares of DKK
0.20, corresponding to 28.3% of the capital and 76.8% of the votes
in Novo Nordisk A/S.
The transaction is in line with the announcement on 5 May 2021
that Novo Holdings A/S intends to maintain its ownership of Novo
Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s incentive
programmes have resulted in a net transfer from Novo Nordisk of
9,954 B shares in the period from 5 May 2021 to 7 May 2021.
With the transactions stated above, Novo Nordisk A/S owns a
total of 11,257,435 B shares of DKK 0.20, corresponding to 0.5% of
the share capital, as treasury shares. The total amount of A and B
shares in the company is 2,310,000,000 of DKK 0.20 including
treasury shares.
About Novo Holdings A/S
Novo Holdings A/S
is a private limited liability company wholly owned by the Novo
Nordisk Foundation. It is the holding company of the Novo Group,
comprising Novo Nordisk A/S and Novozymes A/S, and is responsible
for managing the Novo Nordisk Foundation’s assets. Novo Holdings is
recognized as a leading international life science investor, with a
focus on creating long-term value. As a life science investor, Novo
Holdings provides seed and venture capital to development-stage
companies and takes significant ownership positions in growth and
well-established companies. Novo Holdings also manages a broad
portfolio of diversified financial assets. Further information:
www.novoholdings.dk.
About Novo Nordisk
A/SNovo Nordisk is a leading global healthcare
company, founded in 1923 and headquartered in Denmark. Our purpose
is to drive change to defeat diabetes and other serious chronic
diseases such as obesity and rare blood and endocrine disorders. We
do so by pioneering scientific breakthroughs, expanding access to
our medicines and working to prevent and ultimately cure disease.
Novo Nordisk employs about 45,800 people in 80 countries and
markets its products in around 170 countries. Novo Nordisk's B
shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are
listed on the New York Stock Exchange (NVO). For more information,
visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45
3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Valdemar Borum
Svarrer |
+45 3079
0301 |
jvls@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45
3077 6915 |
dhel@novonordisk.com |
Mark Joseph
Root (US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 31 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024